JBSS32 shares fell 7.82% as of 1:47 PM on Thursday (Dec 11, 2026), dropping from R$ 69.01 to R$ 63.61 while the Ibovespa rose 0.17%. The move exceeded the stock's normal volatility threshold (6.61%) and has a clear catalyst: a BTG Pactual report published the previous day. While the bank maintained its buy rating for JBSS32, it cut its profit estimates for 2027 and signaled that the R$ 2.97 billion acquisition of Flora—against the backdrop of weak Q3 2026 results—raises questions about JBS's capital allocation pace. Trading was still open at the time of this reporting, so the final closing change may differ.
Why Did JBSS32 Fall Today?
No new documents were filed with Brazil's securities regulator, the CVM, in the past 48 hours. The downward pressure stems from a BTG Pactual report released on Tuesday (11/11): the bank kept its buy rating and R$ 100 price target for JBSS32, but lowered its 2027 net income projection by 12%—from $1.22 billion to $1.07 billion—and trimmed its 2027 EBITDA estimate by 3%, from $5.93 billion to $5.75 billion. BTG's core argument is that closing the valuation discount between JBS and its global peers may depend not only on operational delivery, but also on how management handles capital allocation moving forward.
In practical terms, BTG is arguing that the margin-recovery thesis supporting the R$ 100 price target could take longer to materialize if the company keeps making acquisitions before its earnings have normalized. The thesis isn't invalidated—it simply has a delayed timeline. For investors who bought the stock expecting a re-pricing in 2026 or early 2027, the news alters the math.
What BTG Revised and Why Flora Is at the Center of the Debate
The BTG report is the first major institutional analysis attempting to quantify the combined impact of three chained events: third-quarter 2026 results, the Flora acquisition, and the purchase of Canal Rural. As we reported on 11/10, Q3 2026 net income came in at $164 million—down 71% year-over-year—with adjusted EBITDA falling 26.8% to $3.74 billion, pressured by high U.S. cattle costs and compressed American pork margins.
Regarding Flora, BTG noted that the acquisition multiple—7x the target company's EBITDA—drops to 4.9x once factoring in synergies estimated by JBS itself. Flora reported net revenue of R$ 2.9 billion in the 12 months ending September 2026, operates five manufacturing plants, and owns brands such as Minuano, Francis, Neutrox, and OX. Canal Rural was acquired for $11 million. Both transactions are expected to close in December 2026.
The issue raised by BTG isn't the multiple itself, but the context: JBS paid for Flora using treasury shares near their 52-week lows. This means that for every dollar of equity delivered in the transaction, the company handed over more shares than it would have at March price levels. While the resulting dilution to 2027 earnings per share is under 1%—minor on a standalone basis—the opportunity cost of using cheap stock as currency is a signal the market interpreted as suboptimal capital management. The bank also pointed out that free cash flow turned negative in Q3 2026, reinforcing the view that the company pursued M&A during a period of cash constraint.
New Share Issuance? Clearing Up a Persistent Misconception
The most frequent question regarding JBSS32 in recent days centers around a "new issuance." There is no new issuance: JBS paid for Flora with treasury shares rather than newly issued stock launched on the market, as we detailed in our November 9 transaction structure analysis. The confusion is understandable. Treasury shares are previously repurchased stock held by the company; by using them as payment, JBS delivers equity without a formal follow-on offering. For current unitholders, the dilutive effect is real—less than 1% on 2027 earnings per share, according to BTG—but it does exist. What the market is pricing in isn't a share offering, but the broader picture: using cheap stock, posting weak earnings, and entering two new sectors simultaneously while the core business has yet to normalize.
How Industry Peers Fared in the Same Session
The Ibovespa traded higher during the session, and the median absolute change for stocks tracked by the site was 1.54%, making JBS's move an clear outlier. SOJA3 (Boa Safra Sementes) also dropped significantly, falling 5.58%, though that move was driven by stock-specific dynamics detailed in our SOJA3 coverage. Among meatpackers, BEEF3 (Minerva) rose 3.32% in the same session—moving in the opposite direction, which isolates the pressure on JBSS32 and rules out a generalized sector-wide selloff.
The fact that Minerva (BEEF3) rose while JBS fell in the same session confirms that the pressure is specific to the company rather than the protein sector as a whole. JBS trading volume reached R$ 112.1 million by 1:47 PM—above the historical average for that time of day—pointing to significant position liquidation rather than isolated noise.
What We Checked
Documents filed with the CVM in the past 48 hours: none. We reviewed 14 headlines published over the past 24 hours on Google News and our site's archives, two of which directly addressed the price movement: the BTG report and the M&A context. We monitored the Ibovespa and the industry peers listed above. A Money Times headline from November 11 ("JBS remains cheap, but acquisitions raise questions and could delay re-pricing, says BTG") attributes the diagnosis to BTG—it is not our editorial opinion, but the bank's stated view in its report. We found no new material facts disclosed by JBS itself on Thursday.
The company's immediate fundamentals did not change today: the Flora acquisition was already announced, Q3 2026 earnings had been public since Monday, and BTG did not alter its buy rating. What today's session reflects is the market pricing in execution risk—the possibility that margin recovery will take longer than expected while management allocates capital to M&A outside its core protein business. For investors holding the stock, the key metric to monitor isn't today's price, but whether the company can deliver concrete signs of margin normalization over the coming quarters. The calendar begins with the closing of the acquisitions in December, followed by Q4 2026 earnings.
Acquisition closings in December 2026 — JBS expects to finalize the Flora and Canal Rural purchases by December. The market will watch to see if the company provides concrete synergy projections: the estimated drop in the multiple from 7x to 4.9x currently relies on management's projections; confirming those figures will be the operation's first credibility test.
U.S. beef margins in Q4 2026 — BTG maintained a conservative estimate of a 0.5% EBITDA margin for the U.S. operations in 2027. Any result above that level would serve as a major catalyst for the stock's re-pricing; anything below would reinforce the thesis that recovery will be slower.
New M&A announcements — BTG pointed to the pace of acquisitions as the primary risk factor for the thesis timeline. Another purchase announcement, especially outside the core animal protein business, would likely increase selling pressure on the stock while earnings have yet to normalize.
JBSS32 shares fell 7.82% on Dec 11, 2026 (checked at 1:47 PM; trading was still ongoing and final results may vary). The identified cause is a BTG Pactual report published on 11/11, which maintained a buy rating and R$ 100 price target, but cut projected 2027 earnings by 12% and indicated that the M&A pace—acquiring Flora for R$ 2.97 billion and Canal Rural for $11 million using shares near 52-week lows, during a quarter of 71% lower profit and negative cash flow—could delay the stock's re-pricing. The Ibovespa rose during the same period, and BEEF3 gained 3.32%, confirming the pressure is specific to JBS.
